Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 04 2024 - 3:30PM
Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or the “Company”),
a global pharmaceutical company whose mission is to be invaluable
to patients, physicians, and partners concerned with retinal
health, and maintaining better vision longer, today announced that,
pursuant to Nasdaq Listing Rule 5635(c)(4) and in connection with
the appointments of five non-executive employees, the Compensation
Committee of the Board of Directors of the Company (the
“Compensation Committee”) approved, on May 22, 2024 (the “Grant
Date”), inducement awards consisting of stock options under the
Alimera Sciences, Inc. 2024 Equity Inducement Plan to persons who
were not previously employees or who rejoined the Company following
a bona fide period of non-employment, as an inducement material to
each such new or re-hired employee’s employment (collectively, the
“Inducement Awards”).
The Inducement Awards grant the recipients the right to
purchase, in the aggregate, 64,000 shares of common stock of the
Company at an exercise price of $3.00 per share, representing the
closing price of a share of the Company’s common stock on the
Nasdaq Global Market on the Grant Date.
The Inducement Awards will vest over four years, with 25% of the
award vesting on the one-year anniversary of the employment
commencement date and 75% of the award vesting in equal
installments over the following thirty-six (36) months, subject to
continued employment with the Company through each applicable
vesting date.
Each Inducement Award was awarded as an inducement material to
the employee’s commencement of employment in accordance with Nasdaq
Listing Rule 5635(c)(4) and is subject to the terms and conditions
of the Alimera Sciences, Inc. 2024 Equity Inducement Plan and the
grant agreement evidencing the award.
About Alimera Sciences, Inc.
Alimera Sciences is a global pharmaceutical company whose
mission is to be invaluable to patients, physicians and partners
concerned with retinal health and maintaining better vision longer.
For more information, please visit www.alimerasciences.com.
For investor inquiries: |
For media inquiries: |
Scott Gordon |
Jules Abraham |
for Alimera Sciences |
for Alimera Sciences |
scottg@coreir.com |
julesa@coreir.com |
Alimera Sciences (NASDAQ:ALIM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Alimera Sciences (NASDAQ:ALIM)
Historical Stock Chart
From Sep 2023 to Sep 2024